BNET Industries

Market Cap:$1.4B
Last Fiscal Year Sales:$345.3M
  • Public
  • US
Dow Jones Description

Abraxis BioScience is a fully integrated biotechnology company dedicated to delivering progressive therapeutics, such as ABRAXANE, and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. Abraxis' portfolio includes the world's first and only protein-based nanoparticle chemotherapeutic compound. Scientists at Abraxis developed its proprietary tumor targeting system known as the nab Technology platform, an innovative approach to treating cancer and other critical illnesses. By harnessing the unique natural properties of the human protein albumin, Abraxis' nab technology platform enables the transport and delivery of therapeutic agents to the site of disease. This revolutionary biologically interactive delivery system is being further developed with other water insoluble drugs for their potential use across a broad range of tumors. ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), the first U.S. Food and Drug Administration (FDA) approved product to use the nab platform, was launched in 2005 for the treatment of metastatic breast cancer. From the discovery and research phase to development and commercialization, Abraxis BioScience is committed to rapidly enriching the company's pipeline and accelerating the delivery of breakthrough therapies that will transform the lives of the patients who need them. ...

Vice Chairman, President & CEO
Leon O. Moulder
Number of Employees 734
Contact Information

11755 Wilshire Blvd Ste 2000

Los Angeles, California 90025

www.abraxisbio....

(310) 883-1300

NAICS Code Medical Laboratories: 621511

Recent Events

  • Abraxis BioScience Reports 2009 Third Quarter Financial Results

    11/05/09 - Financial Announcement - View Story

  • Abraxis BioScience Names Rick Rodgers Succeeding David O'Toole As CFO - Update

    7/10/09 - Mgmt. Change Leaving - Vice President - View Story

  • BRIEF-Abraxis Bioscience names Rick Rodgers chief financial officer

    7/10/09 - Mgmt. Change Entering - CFO - View Story

  • Market Report -- In Play ABII

    7/10/09 - Mgmt. Change Entering - Vice President - View Story

  • Abraxis BioScience Appoints CFO

    7/15/09 - Mgmt. Change Entering - CFO - View Story

News & Analysis

abraxis bioscience inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Thomas H. Silberg President and Chief Executive Officer
David D. O. Toole Executive Vice President and Chief Financial Officer
David O'Toole CFO & Executive Vice President
David O. Toole Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)
Mary Lynne Hedley Executive Vice President of Operations & Cso
Richard J. Rodgers Senior Vice President and CFO
Bruce J. Wendel Executive. Vice President Corporate Development
Ed Geehr Executive Vice President Operations
Marty Duvall Senior Vice President, Global Marketing & Intl Commercial Operations

Board of Directors

Name (plus bio) Position
Leon O. Moulder Vice Chairman, President & CEO
David S. Chen Board of Directors
Kirk K. Calhoun Board of Directors
Leonard Shapiro Board of Directors
Maili Bergman Board of Directors
Patrick Soon-Shiong Board of Directors
Stephen D. Nimer Board of Directors
Steven Hassen Board of Directors

Organization Position Status
Abraxis Biosciences, Inc. Vice Chairman, President & CEO Current
Abraxis Biosciences, Inc. Board of Directors Current

Organization Position Status
Abraxis Biosciences, Inc. President and Chief Executive Officer Current

Organization Position Status
Abraxis Biosciences, Inc. Executive Vice President and Chief Financial Officer Current

David O'Toole joined Abraxis in 2008 with more than 24 years of experience in financial consulting and international tax services to global companies, and particular expertise in the life sciences industry. Before joining the team at Abraxis BioScience, Mr. O'Toole was with Deloitte & Touche LLP for 16 years, last serving as Partner - Strategic Client Group. There he was responsible for providing solutions to issues facing the life sciences industry, including enterprise cost reduction, commercialization and distribution of drugs, human resources, Sarbanes Oxley compliance and international tax planning. Mr. O'Toole was also Deloitte's Life Science leader in the Pacific Southwest for the last two years, helping to build their industry eminence in the marketplace. Mr. O'Toole's international experience includes a two year assignment in Paris, France, during which he was a consultant to large and medium-sized multi-national companies with an emphasis on cross border operational and tax planning. He also had a two year assignment in Tokyo, Japan. Mr. O'Toole earned his bachelor of science degree in accounting from the University of Arizona. He is a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants, the California Healthcare Institute and the Southern California Biomedical Counsel.

Organization Position Status
Abraxis Biosciences, Inc. CFO & Executive Vice President Current
California Society of Certified Public Accountants Board of Directors Current
The University of Arizona Bachelor of Science Degree In Accounting Former

Organization Position Status
Abraxis Biosciences, Inc. Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) Current

Organization Position Status
Abraxis Biosciences, Inc. Executive Vice President of Operations & Cso Current

Organization Position Status
Abraxis Biosciences, Inc. Senior Vice President and CFO Current

Organization Position Status
Abraxis Biosciences, Inc. Executive. Vice President Corporate Development Current
American Bioscience Inc. Executive Vice President, Corporate Development Current
APP Pharmaceuticals, Inc. Executive Vice President, Corp Dev Current
Bristol-Myers Squibb Company Vice President, Corporate Development International Medicines Former
APP Pharmaceuticals, Inc. Vice President of Corporate Development Former
IVAX Corporation Vice President, Business Development Former
Bristol-Myers Squibb Company In, House Counsel Former
SmithKline Beecham Corporation Former
Georgetown University Juris Doctorate degree Former
Georgetown Law School Jd Former
Cornell University BS Former

Organization Position Status
Abraxis Biosciences, Inc. Executive Vice President Operations Current

Organization Position Status
Abraxis Biosciences, Inc. Senior Vice President, Global Marketing & Intl Commercial Operations Current

David S. Chen, Ph.D. has served as a director since the separation in November 2007. Dr. Chen previously served as a director of Old Abraxis from June 1998 to the date of the separation. Dr. Chen has been a senior executive vice president of China Development Industrial Bank since February 2004. Dr. Chen also served as president of China Trust Venture Capital Corporation from October 2001 to May 2004 and was the chairman of Cypac Investment Management Limited from 1998-2001. He served as chief executive officer of Central Investment Holdings Company from July 1996 to February 2000, and chief financial officer from May 1991 to February 1994. Dr. Chen holds a B.S. in agricultural economics from National Taiwan University, a M.B.A. from California State University at Long Beach and a Ph.D. in business administration from Nova University, Florida.

Organization Position Status
China Development Industrial Bank, Inc. Senior Executive Vice President Current
Abraxis Biosciences, Inc. Board of Directors Current
California State University M.B.A. Former

Organization Position Status
Cardiovascular Systems, Inc. Chairman Current
Adams Respiratory Therapeutics, Inc. Chairman Current
Aspreva Pharmaceuticals Corporation Chairman Current
Adams Laboratories, Inc. Board of Directors Current
Response Genetics Board of Directors Current
Abraxis Biosciences, Inc. Board of Directors Current
APP Pharmaceuticals, Inc. Board of Directors Current
Ernst & Young partner Former
Cardiovascular Systems, Inc. Board of Directors Former
Adams Respiratory Therapeutics, Inc. Board of Directors Former
Aspreva Pharmaceuticals Corporation Board of Directors Former
University of Southern California B.S. in Accounting Former

Organization Position Status
Shapco, Inc. Founder Current
Abraxis Biosciences, Inc. Board of Directors Current
Kelly Pipe Div. President, Shapco Former
Shapco, Inc. CEO Former
Shapco, Inc. President Former

Organization Position Status
Abraxis Biosciences, Inc. Board of Directors Current

Organization Position Status
American College of Surgeons Fellow Current
APP Pharmaceuticals, Inc. Board Chairman Current
Abraxis Biosciences, Inc. Board of Directors Current
American College of Surgeons Fellow Current
APP Pharmaceuticals, Inc. CEO Former
Abraxis Biosciences, Inc. Chairman and Chief Executive Officer Former
American Bioscience Inc. President Former
American Bioscience Inc. Cfo Former
APP Pharmaceuticals, Inc. Board Director Former
American Bioscience Inc. Board Director Former
University of British Columbia M.Sc Former
University of the Witwatersrand Degree Former

Dr. Nimer is Professor of Medicine and Professor of Pharmacology at Weill Medical College of Cornell University. He also serves as Chief of Hematology Service and Head of the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York City. Dr. Nimer is a member of many national professional organizations, including the American Society of Hematology, the American Society of Clinical Oncology, and the International Society for Stem Cell Research. He serves as a Reviewer for major medical journals, including the New England Journal of Medicine and the Journal of the American Medical Association (JAMA) among many others. He serves on numerous national and international Grant Review Committees and is a prominent invited speaker at conferences on his areas of expertise. He has authored or co-authored nearly 200 peer-reviewed papers, reviews, editorials and textbook chapters, primarily focused on issues concerning hematology and oncology

Organization Position Status
Memorial Sloan-Kettering Cancer Center Inc. Chief of Hematology Service Current
New England Journal of Medicine Reviewer Current
Memorial Hospital, Inc Attending Physician Current
The G&P Foundation for Cancer Research Chairman Current
Abraxis Biosciences, Inc. Board of Directors Current
American Society of Clinical Oncology Board of Directors Current
American Society of Hematology Board of Directors Current
Genpath Board of Directors Current
Neostem, Inc. Board of Directors Current
American Association for Cancer Research, Inc. Board of Directors Current
Onconova Therapeutics, Inc Board of Directors Current
APP Pharmaceuticals, Inc. Board of Directors Current
American Society of Hematology Member Current
American Association for Cancer Research, Inc. Member Current
American College of Physicians Fellow Current
Memorial Sloan-Kettering Cancer Center Inc. Head Former
University of California, Los Angeles Former
Cancer Research Chairman Former
University of Chicago M.D. Former
Massachusetts, Inc. B.S. In Biology Former
Massachusetts Institute of Technology B.S. in Biology Former
University of Chicago Pritzker School of Medicine Degree Former

Organization Position Status
Abraxis Biosciences, Inc. Board of Directors Current
advertisement
     ABII $35.13 0.00 (0.00% )
Average Volume 59,277
Shares Outstanding 40.12M
Market Cap 1.4B
Year High 74.5
Year Low 24.52
Earnings Per Share -6.07
P/E Ratio -5.79
Dividend N/A
Yield N/A
advertisement